Report Library
All Reports
2015 Breast Cancer Development Update Slidedeck
May 29, 2015
This slidedeck provides an overview of major events and changes in the breast cancer development pipeline since June 2014. We
discuss the following points in a series of figures and tables:
For our disclosures, please read the BioMedTracker Research Standards.
- New breast cancer drug approval: Ibrance (palbociclib, PFE)
- Negative registrational trial data: Nexavar (sorafenib, AMGN and Bayer), Etirinotecan pegol (NKTR)
- Pipeline phase advancements and major development suspensions
- Characteristics of approved and pipeline agents for breast cancer, based on molecular class and molecular target.
For our disclosures, please read the BioMedTracker Research Standards.
| Indications Covered: | Breast Cancer |
Additional Resources: